News from the Beijing News On May 9, Kelun Pharmaceuticals issued an announcement that Shugeng Sodium Glucose Injection was approved by the State Food and Drug Administration for drug registration, used to antagonize rocuronium bromide or vecuronium bromide Induced neuromuscular blockade.
Sugain Glucose Sodium Injection is a selective neuromuscular blocking antagonist developed by Merck & Co. The country was approved for listing, and domestic import was approved in 2017.
Sugammadex sodium is a major discovery in the field of anesthesia in the past 20 years. It is the world’s first and only specific binding neuromuscular blockade antagonist. During the operation, the muscle relaxation effect of different depths can be quickly, efficiently and completely reversed, which can promote the recovery of spontaneous breathing and limb movement of patients, and help improve the postoperative rehabilitation of patients. “, the French “Guidelines for Muscle Relaxants and Anesthesia Reversal (2020)” and other domestic and foreign authoritative guidelines or consensus recommendations. The global sales of Sugammadex Sodium Injection in 2021 will exceed US$1.5 billion.
Proofreading Zhao Lin